Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
November 29, 2017

Cases of DME among the diabetic retinopathy population to increase

The burden of diabetic macular edema (DME) among the diagnosed diabetic retinopathy population in the seven major markets (7MM: US, 5EU [France, Germany, Italy, Spain, UK], and Japan) is expected to grow between 2016 and 2026.

The burden of diabetic macular edema (DME) among the diagnosed diabetic retinopathy population in the seven major markets (7MM: US, 5EU [France, Germany, Italy, Spain, UK], and Japan) is expected to grow between 2016 and 2026. GlobalData epidemiologists forecast an increase in the number of diagnosed prevalent cases of DME among the diagnosed diabetic retinopathy population, most notably in the 5EU and the US. Figure 1 presents the expected changes in the 7MM from 2016 to 2026.

Macular edema (ME) is a condition characterised by the thickening and swelling (edema) of the macula, which is the area of the retina that is responsible for central vision. ME occurs when there is abnormal leakage and accumulation of fluid in the macula from damaged blood vessels in the nearby retina. The occurrence of ME is highly frequent in diabetics and usually manifests itself as DME. DME is often a complication of diabetic retinopathy, defined as a retinal thickening involving or approaching the center of the macula, and is the most common cause of vision loss in patients affected by diabetes mellitus, especially if left untreated.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of DME in the diagnosed retinopathy population will grow by 31.29% over the forecast period, at an Annual Growth Rate (AGR) of 3.13%, from 980,030 cases in 2016 to 1,286,637 cases in 2026. In 2016, the US accounted for 30.33% of the diagnosed prevalent cases of DME among the diabetic retinopathy population in 7MM, with 297,261 cases. There were 310,601 cases in the 5EU, or 31.69% of the diagnosed prevalent cases, while Japan had 372,168 diagnosed prevalent cases, accounting for 37.98% of the diagnosed prevalent cases in the 7MM. Of the 7MM, the US is expected to have the highest number of diagnosed prevalent cases, increasing from 297,261 in 2016 to 439,658 in 2026.

Details about the trend analysis and other discussions of macular edema epidemiology can be found in the EpiCast Report: Macular Edema – Epidemiology Forecast to 2026 and the EpiCast Model: Macular Edema – Epidemiology Forecast to 2026.

Related Companies

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU